Status:

COMPLETED

Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease

Lead Sponsor:

The Rogosin Institute

Collaborating Sponsors:

Janssen Research & Development, LLC

Conditions:

Proteinuria

Kidney Injury

Eligibility:

All Genders

18-90 years

Brief Summary

This study will evaluate in patients with kidney disease, the role that certain inflammatory and immune mediators play in promoting kidney damage. The investigators hypothesize that certain mediators,...

Detailed Description

The aim of the study is to evaluate in humans inflammatory and immune mediators that may play a role in kidney damage. The investigators hypothesize that certain inflammatory and immune mediators iden...

Eligibility Criteria

Inclusion

  • Male and females, 18 years to 90 years old
  • Any subject with pre-existing clinical indication of a kidney biopsy including, but not limited to, nephritic syndrome, nephritic syndrome or proteinuric disease state. Additionally, kidney transplant donors will be included for purpose of obtaining control tissue.
  • Willing and able to give consent
  • Additionally, kidney transplant donors and patients requiring nephrectomy for removal of renal mass will be included for purpose of obtaining control tissue.

Exclusion

  • Subjects on longstanding immunosuppressive agents (empiric initiation of glucocorticoid therapy within 48 hours prior to kidney biopsy is acceptable)
  • Kidney transplant recipient
  • Inability to follow-up for future protocol laboratory evaluation

Key Trial Info

Start Date :

July 1 2010

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 1 2016

Estimated Enrollment :

119 Patients enrolled

Trial Details

Trial ID

NCT01156428

Start Date

July 1 2010

End Date

November 1 2016

Last Update

March 15 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Rogosin Institute

New York, New York, United States, 10021